Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154986
Status:
UNKNOWN
Last Update Posted:
2005-09-12
First Post:
2005-09-09
Brief Title:
IGFBP-3 in Ovarian Cancer Invasion
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Study of IGFBP-3 in the Ovarian Carcinoma Cell Invasion
Status:
UNKNOWN
Status Verified Date:
2004-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An ovarian cancer cell line OVTW-59 derived from an ovarian endometrioid carcinoma was established and its sublines labeled as P0 P1 P2 P3 and P4 with increasing invasion abilities were selected from transwell invasion chambersUsing cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction we have identified IGFBP-3 as an invasion-suppressor gene We plan to study the role of IGFBP-3 in ovarian cancer invasion
Detailed Description:
We have successfully established an ovarian cancer cell line OVTW-59 which was derived from an ovarian endometrioid carcinoma Its sublines labeled as P0 P1 P2 P3 and P4 with increasing invasion abilities were selected from transwell invasion chambers where P0 represented the original cell line at 100th passage By using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction we have identified the differentially gene expression profiles of these OVTW-59 series cell lines in order to identify the invasion related suppressor and oncogenes from ovarian carcinoma From these genes we selected insulin-like growth factor binding protein IGFBP-3 which is a suppressor gene and found it lower expressed in higher-grade tumors and correlated with poor patient survival In vitro we found IGFBP-3 related to the inhibition of cancer cell migration In this study we plan to setup stable transfected IGFBP-3 cell lines in P0 and P4 and study the relationship among IGFBP-3 metalloproteinase-2 our previous studies which verified its relationship with tumor invasiveness and insulin-like growth factor IGF-1 We would study the changes in cytoskeletal structures and the known functions of anti-proliferation and apoptosis in IGFBP-3 Furthermore we would like to investigate the mechanism of IGFBP-3 in the inhibition of invasionmigration of ovarian carcinoma either signaling through MAPK or PI3KAKT pathways Finally through xenograft we plan to study for the possible application of IGFBP-3 in ovarian cancer therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NSC93-2314-B-002-168 | None | None | None |